108307-65-9
Chemical Structure
RB-90740
- CAS No.: 108307-65-9
- Formula:C20H22N6O
- Molecular Weight:362.43
IUPAC Name: 2-(4-methylpiperazin-1-yl)-6-phenyl-8,9-dihydroimidazo[1,2-a]pyrido[3,2-e]pyrazine 5-oxide
InChIKey: CKRPRSXFNWNTOW-UHFFFAOYSA-N
SMILES: CN1CCN(CC1)C2=CC=C3[N+]([O-])=C(C4=NCCN4C3=N2)C5=CC=CC=C5
Biological Activity: RB-90740 is a type of biological reducing agent. RB-90740 is activated through metabolic reduction and generates cytotoxic products, thereby selectively killing tumor cells (usually in a hypoxic environment). RB-90740 has selective toxicity towards hypoxic cells, which is mainly achieved by causing DNA strand breaks and activating reducing enzymes (such as Cytochrome P450). RB-90740 does not initially exhibit cytotoxicity similar to its in vitro properties in hypoxic cells in mouse models. RB-90740 can be used to study the tumor physiological environment[1][2]
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RB-90740 | RB-90740 is a type of biological reducing agent. RB-90740 is activated through metabolic reduction and generates cytotoxic products, thereby selectively killing tumor cells (usually in a hypoxic environment). RB-90740 has selective toxicity towards hypoxic cells, which is mainly achieved by causing DNA strand breaks and activating reducing enzymes (such as Cytochrome P450). RB-90740 does not initially exhibit cytotoxicity similar to its in vitro properties in hypoxic cells in mouse models. RB-90740 can be used to study the tumor physiological environment | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Adams GE, Stratford IJ. Bioreductive drugs for cancer therapy: the search for tumor specificity. International Journal of Radiation Oncology* Biology* Physics. 1994 May 15;29(2):231-8.
- [2]. Naylor MA, et al. Fused pyrazine mono-N-oxides as bioreductive drugs III. Characterization of RB 90740 in vitro and in vivo. Anti-Cancer Drugs. 1995 Apr 1;6(2):259-69.
